Margetuximab

Drug Profile

Margetuximab

Alternative Names: Anti-HER2-monoclonal-antibody-Green-Cross; MGAH-22

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Raven biotechnologies
  • Developer Green Cross; MacroGenics; Merck Sharp & Dohme
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase I/II Gastric cancer
  • No development reported Bladder cancer; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Bladder-cancer in South Korea (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Bladder-cancer in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer in South Korea (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top